Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.12.2012 | Clinical trial

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer

verfasst von: C. F. Jehn, B. Flath, A. Strux, M. Krebs, K. Possinger, A. Pezzutto, D. Lüftner

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Depression and anxiety are the core disorders causing emotional distress in patients (pts) with metastatic breast cancer. The aim of our study was to screen metastatic breast cancer outpatients for anxiety and depression, and to investigate the influence of age, Karnofsky Performance Status (KPS), cancer activity, and inflammation as represented by IL-6 levels on these two mood disorders. Pts treated with chemotherapy for metastatic breast cancer (n = 70) were assessed using the Hospital Anxiety and Depression Scale (HADS) for symptoms (scores 0–21) and caseness (score ≥11) of clinical depression and anxiety. Blood samples for IL-6 concentrations were collected at 10:00 a.m. A total of 22 (31.4 %) pts were diagnosed with caseness of clinical depression and 23 (32.9 %) pts with clinical anxiety, while 12 pts were diagnosed positive for both mood disorders. Depression and anxiety were positively but moderately correlated (Spearman’s r 2 = 0.24, p < 0.001). IL-6 was significantly correlated with symptoms of depression (r 2 = 0.42, p < 0.001) and to a lesser extent to symptoms of anxiety (r 2 = 0.16, p = 0.001). In addition, IL-6 was positively associated with tumor progression (p < 0.001). Multiple linear regression analysis showed that tumor progression (standardized b = 0.226, p = 0.047), symptoms of anxiety (b = 0.292, p = 0.016), and IL-6 (b = 0.314, p = 0.007) were independently associated with clinical depression, whereas anxiety was linked to tumor progression (b = 0.238, p = 0.030), symptoms of depression (b = 0.407, p < 0.001) and age (b = −0.381, p < 0.001), but not to IL-6 (b = 0.168, p = 0.134). Even though a positive correlation between depression and anxiety exists, clinical parameters like age, cancer activity, KPS, and IL-6 do influence depression and anxiety differently. Unlike clinical depression, anxiety is not associated with increased IL-6 levels, however, shows a reciprocal correlation with age.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef
2.
Zurück zum Zitat Costa D, Mogos I, Toma T (1985) Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand Suppl 320:85–92PubMedCrossRef Costa D, Mogos I, Toma T (1985) Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand Suppl 320:85–92PubMedCrossRef
3.
Zurück zum Zitat Stoudemire A, Thompson TL (1983) Medication noncompliance: systematic approaches to evaluation and intervention. Gen Hosp Psychiatr 5(4):233–239CrossRef Stoudemire A, Thompson TL (1983) Medication noncompliance: systematic approaches to evaluation and intervention. Gen Hosp Psychiatr 5(4):233–239CrossRef
4.
Zurück zum Zitat Koenig HG, Shelp F, Goli V, Cohen HJ, Blazer DG (1989) Survival and health care utilization in elderly medical inpatients with major depression. J Am Geriatr Soc 37(7):599–606PubMed Koenig HG, Shelp F, Goli V, Cohen HJ, Blazer DG (1989) Survival and health care utilization in elderly medical inpatients with major depression. J Am Geriatr Soc 37(7):599–606PubMed
5.
6.
Zurück zum Zitat Ashbury FD, Findlay H, Reynolds B, McKerracher K (1998) A Canadian survey of cancer patients’ experiences: are their needs being met? J Pain Symptom Manag 16(5):298–306CrossRef Ashbury FD, Findlay H, Reynolds B, McKerracher K (1998) A Canadian survey of cancer patients’ experiences: are their needs being met? J Pain Symptom Manag 16(5):298–306CrossRef
7.
Zurück zum Zitat Van’t Spijker A, Trijsburg RW, Duivenvoorden HJ (1997) Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med 59(3):280–293PubMed Van’t Spijker A, Trijsburg RW, Duivenvoorden HJ (1997) Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med 59(3):280–293PubMed
8.
Zurück zum Zitat Rabe-Jablonska J, Bienkiewicz W (1994) Anxiety disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association: diagnostic and statistical manual of mental disorders (DMS-IV––options book. Psychiatr Pol 28(2):255–268PubMed Rabe-Jablonska J, Bienkiewicz W (1994) Anxiety disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association: diagnostic and statistical manual of mental disorders (DMS-IV––options book. Psychiatr Pol 28(2):255–268PubMed
9.
Zurück zum Zitat Katon W, Sullivan MD (1990) Depression and chronic medical illness. J Clin Psychiatr 51(Suppl):3–11 Katon W, Sullivan MD (1990) Depression and chronic medical illness. J Clin Psychiatr 51(Suppl):3–11
10.
Zurück zum Zitat Aapro M, Cull A (1999) Depression in breast cancer patients: the need for treatment. Ann Oncol 10(6):627–636PubMedCrossRef Aapro M, Cull A (1999) Depression in breast cancer patients: the need for treatment. Ann Oncol 10(6):627–636PubMedCrossRef
11.
Zurück zum Zitat Jenkins R, Bebbington P, Brugha T et al (2003) British Psychiatric Morbidity Survey. Int Rev Psychiatr 15(1–2):14–18CrossRef Jenkins R, Bebbington P, Brugha T et al (2003) British Psychiatric Morbidity Survey. Int Rev Psychiatr 15(1–2):14–18CrossRef
12.
Zurück zum Zitat Cassileth BR, Lusk EJ, Hutter R, Strouse TB, Brown LL (1984) Concordance of depression and anxiety in patients with cancer. Psychol Rep 54(2):588–590PubMedCrossRef Cassileth BR, Lusk EJ, Hutter R, Strouse TB, Brown LL (1984) Concordance of depression and anxiety in patients with cancer. Psychol Rep 54(2):588–590PubMedCrossRef
13.
Zurück zum Zitat Danzer K (1993) The new education for the care of the well and the ill may start. Osterr Krankenpfl 46(2):8–10 Danzer K (1993) The new education for the care of the well and the ill may start. Osterr Krankenpfl 46(2):8–10
14.
Zurück zum Zitat Dentino AN, Pieper CF, Rao MK et al (1999) Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 47(1):6–11PubMed Dentino AN, Pieper CF, Rao MK et al (1999) Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 47(1):6–11PubMed
15.
Zurück zum Zitat Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic–pituitary–adrenal axis in humans. J Clin Endocrinol Metab 77(6):1690–1694PubMedCrossRef Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic–pituitary–adrenal axis in humans. J Clin Endocrinol Metab 77(6):1690–1694PubMedCrossRef
16.
Zurück zum Zitat Sluzewska A, Rybakowski J, Bosmans E et al (1996) Indicators of immune activation in major depression. Psychiatr Res 64(3):161–167CrossRef Sluzewska A, Rybakowski J, Bosmans E et al (1996) Indicators of immune activation in major depression. Psychiatr Res 64(3):161–167CrossRef
17.
Zurück zum Zitat Musselman DL, Miller AH, Porter MR et al (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatr 158(8):1252–1257PubMedCrossRef Musselman DL, Miller AH, Porter MR et al (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatr 158(8):1252–1257PubMedCrossRef
18.
Zurück zum Zitat Karnofsky DA, Burchenal JH (1950) Present status of clinical cancer chemotherapy. Am J Med 8(6):767–788PubMedCrossRef Karnofsky DA, Burchenal JH (1950) Present status of clinical cancer chemotherapy. Am J Med 8(6):767–788PubMedCrossRef
19.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
20.
Zurück zum Zitat Iconomou G, Mega V, Koutras A, Iconomou AV, Kalofonos HP (2004) Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 101(2):404–411PubMedCrossRef Iconomou G, Mega V, Koutras A, Iconomou AV, Kalofonos HP (2004) Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 101(2):404–411PubMedCrossRef
21.
Zurück zum Zitat Herrmann C (1997) International experiences with the hospital anxiety and depression scale––a review of validation data and clinical results. J Psychosom Res 42(1):17–41PubMedCrossRef Herrmann C (1997) International experiences with the hospital anxiety and depression scale––a review of validation data and clinical results. J Psychosom Res 42(1):17–41PubMedCrossRef
22.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMedCrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMedCrossRef
23.
Zurück zum Zitat Moorey S, Greer S, Watson M et al (1991) The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatr 158:255–259CrossRef Moorey S, Greer S, Watson M et al (1991) The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatr 158:255–259CrossRef
24.
Zurück zum Zitat American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington
25.
Zurück zum Zitat Flower L, Humphries SE, Mohamed-Ali V et al (2000) Effects of sample handling on the stability of interleukin-6, tumor necrosis factor-a and leptin. Cytokine 12:1712–1716PubMedCrossRef Flower L, Humphries SE, Mohamed-Ali V et al (2000) Effects of sample handling on the stability of interleukin-6, tumor necrosis factor-a and leptin. Cytokine 12:1712–1716PubMedCrossRef
26.
Zurück zum Zitat Noyes R, Kathol RG, Debelius-Enemark P et al (1990) Distress associated with cancer as measured by illness distress scale. Psychosomatics 31:321–330PubMedCrossRef Noyes R, Kathol RG, Debelius-Enemark P et al (1990) Distress associated with cancer as measured by illness distress scale. Psychosomatics 31:321–330PubMedCrossRef
27.
Zurück zum Zitat Massie MJ et al (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71PubMedCrossRef Massie MJ et al (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71PubMedCrossRef
28.
Zurück zum Zitat Pierce BL, Ballard-Barbash R, Berstein L et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444PubMedCrossRef Pierce BL, Ballard-Barbash R, Berstein L et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444PubMedCrossRef
29.
Zurück zum Zitat Salgado R, Junius S, Benoy I et al (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642–646PubMedCrossRef Salgado R, Junius S, Benoy I et al (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642–646PubMedCrossRef
30.
Zurück zum Zitat Zhang GJ, Adachi I et al (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19:1427–1432PubMed Zhang GJ, Adachi I et al (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19:1427–1432PubMed
31.
Zurück zum Zitat Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef
32.
33.
Zurück zum Zitat Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef
34.
Zurück zum Zitat Ford DE, Erlinger TP et al (2004) Depression and C-reactive protein in US adult: data from the third National Health and Nutrition Examination Survey. Arch Intern Med 164:1010–1014PubMedCrossRef Ford DE, Erlinger TP et al (2004) Depression and C-reactive protein in US adult: data from the third National Health and Nutrition Examination Survey. Arch Intern Med 164:1010–1014PubMedCrossRef
35.
Zurück zum Zitat Banks J, Marmot M, Oldfield Z et al (2006) Disease and disadvantage in the United States and in England. JAMA 295:2037–2045PubMedCrossRef Banks J, Marmot M, Oldfield Z et al (2006) Disease and disadvantage in the United States and in England. JAMA 295:2037–2045PubMedCrossRef
Metadaten
Titel
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer
verfasst von
C. F. Jehn
B. Flath
A. Strux
M. Krebs
K. Possinger
A. Pezzutto
D. Lüftner
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2311-2

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.